Skip to content

Effectiveness of Contextual Schema Therapy on Emotion Regulation, Interpersonal Problems, Painful Physical Symptoms, Fear of Negative and Positive Evaluation in Individuals with Social Anxiety Disorder

Effectiveness of Contextual Schema Therapy on Emotion Regulation, Interpersonal Problems, Painful Physical Symptoms, Fear of Negative and Positive Evaluation in Individuals with Social Anxiety Disorder: Single Subject Design

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211006052690N1
Enrollment
12
Registered
2021-10-26
Start date
2021-10-19
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Anxiety Disorder. Social phobias

Interventions

Contextual Schema Therapy will be performed on the subjects in the form of the Single Subject Design for 16 sessions of 1 hour per week. Contextual Schema Therapy will be performed on the subjects in
An Integrative Approach to Personality Disorders, Emotional Dysregulation, and Interpersonal Functioning." The authors of this book are Eckhard Roediger, Bruce A. Stevens and Robert Brockman. Context
to confront harmful internal messengers
and to access and protect Vulnerable Modes, while strengthening the Healthy Adult Mode in order to thwart self-defeating patterns in favor of healthier responses. Therefore, the reason for naming this

Sponsors

The Ferdowsi University of Mashhad
Lead Sponsor
The Semnan University
Collaborator

Eligibility

Sex/Gender
All
Age
20 Years to 30 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Social Anxiety Disorder based on Structured Clinical Interview for DSM-5 (SCID-5) Age range 20 to 30 Years Level of education, minimum diploma Consent of the participants to attend the treatment sessions

Exclusion criteria

Exclusion criteria: Psychiatric disorders such as psychotic disorders and personality disorders and comorbid disorders such as other anxiety disorders, mood disorders, body dysmorphic disorder and substance use disorders Addictive behaviors such as Internet Addiction (measured in the context of the interview) Medical disorders (assessment by reviewing the file and medical history) Receiving simultaneous psychological interventions

Design outcomes

Primary

MeasureTime frame
Fear of Positive Evaluation score on the Fear of Positive Evaluation Scale (FPES). Timepoint: The variable will be assessed one week before the start of treatment and at the baseline stage. It will then be assessed four times during treatment. At the end of treatment and then with a 3 months follow-up, the assessment will be repeated. Method of measurement: Fear of Positive Evaluation Scale (FPES).;Emotion regulation score in the Emotion Regulation Questionnaire (ERQ). Timepoint: The variable will be assessed one week before the start of treatment and at the baseline stage. It will then be assessed four times during treatment. At the end of treatment and then with a 3 months follow-up, the assessment will be repeated. Method of measurement: Emotion Regulation Questionnaire (ERQ).;Interpersonal Problems score in the Inventory of Interpersonal Problems (IIP-32). Timepoint: The variable will be assessed one week before the start of treatment and at the baseline stage. It will then be assessed four times during treatment. At the end of treatment and then with a 3 months follow-up, the assessment will be repeated. Method of measurement: Inventory of Interpersonal Problems (IIP-32).;Score of Painful Physical Symptoms in the Visual Analogue Scale (VAS). Timepoint: The variable will be assessed one week before the start of treatment and at the baseline stage. It will then be assessed four times during treatment. At the end of treatment and then with a 3 months follow-up, the assessment will be repeated. Method of measurement: Visual Analogue Scale (VAS).;Fear of Negative Evaluation score in the Brief Fear of Negative Evaluation-II (BFNE-II). Timepoint: The variable will be assessed one week before the start of treatment and at the baseline stage. It will then be assessed four times during treatment. At the end of treatment and then with a 3 months follow-up, the assessment will be repeated. Method of measurement: Brief Fear of Negative Evaluation-II (BFNE-II).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Issac Rahimian Boogar

The Semnan University

i_rahimian@semnan.ac.ir+982333623300- +982333624250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026